The project intends to determine the causes of Parkinson’s disease by mapping biological mutations of the Leucine-rich repeat kinase 2 (LRRK2) protein, which is believed to be the key cause of the disease.
The biological maps which are said to support the drug discovery process for treating PD will trace the disease’s biological pathways find relevant biomarkers, which signal an abnormal process or disease.
Thomson Reuters creates biological maps using scientific literature data that is manually annotated using the business’s curation methods.
The data selected for the maps is then assessed based on select criteria to ensure depth, breadth and quality of information for the researchers using it.
Thomson Reuters Life Sciences executive vice president Jon Brett-Harris said the maps developed by the company would provide further insights into Parkinson’s disease and its cause.
"The maps will provide PD researchers with a resource to reveal the mechanisms behind the disease and further extend the drug discovery process," Brett-Harris added.